Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval

Year after acquiring HRA, Perrigo makes preparations to launch arguably the most anticipated OTC switch in US pharma history, Opill with 0.075-mg norgestel. Analysts estimate $100m annual market for OTC birth control.

Perrigo Company PLC has made notable progress before in its pivot from focusing its US OTC drug business on providing generic copies of OTC national brands to making and marketing national brands.

The transition’s biggest step to date came on 13 July with the Food and Drug Administration’s approval of the application...